380 related articles for article (PubMed ID: 26795291)
21. 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake.
Luo Y; Yu M; Pan Q; Wu W; Zhang T; Kiesewetter DO; Zhu Z; Li F; Chen X; Zhao Y
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):531-2. PubMed ID: 25398421
[No Abstract] [Full Text] [Related]
22. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
23. Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT.
Michalski K; Laubner K; Stoykow C; Omrane MA; Maecke HR; Seufert J; Goetz C; Meyer PT; Ruf J
Clin Nucl Med; 2020 Jul; 45(7):519-524. PubMed ID: 32453080
[TBL] [Abstract][Full Text] [Related]
24. Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.
Läppchen T; Tönnesmann R; Eersels J; Meyer PT; Maecke HR; Rylova SN
PLoS One; 2017; 12(1):e0170435. PubMed ID: 28103285
[TBL] [Abstract][Full Text] [Related]
25.
Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
[TBL] [Abstract][Full Text] [Related]
26. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.
Sowa-Staszczak A; Pach D; Mikołajczak R; Mäcke H; Jabrocka-Hybel A; Stefańska A; Tomaszuk M; Janota B; Gilis-Januszewska A; Małecki M; Kamiński G; Kowalska A; Kulig J; Matyja A; Osuch C; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):524-31. PubMed ID: 23224740
[TBL] [Abstract][Full Text] [Related]
27. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
29. Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.
Garg R; Shah R; Tiwari A; Purandare N; Lele VR; Malhotra G; Verma P; Gosavi V; Dalvi A; Kumar Jaiswal S; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2020 Dec; 93(6):678-686. PubMed ID: 32716527
[TBL] [Abstract][Full Text] [Related]
30. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
31. Morphologically 'invisible' proinsulin - secreting adenoma detected by Ga-68 Exendin-4 (GLP-1 Receptor) positron emission tomography/CT.
Werner C; Lupp A; Drescher R; Freesmeyer M; Mireskandari M; Stoykow C; Bauschke A; Müller UA
J Med Imaging Radiat Oncol; 2018 Jun; 62(3):370-374. PubMed ID: 29399966
[TBL] [Abstract][Full Text] [Related]
32. 68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1.
Antwi K; Nicolas G; Fani M; Heye T; Pattou F; Grossman A; Chanson P; Reubi JC; Perren A; Gloor B; Vogt DR; Wild D; Christ E
J Clin Endocrinol Metab; 2019 Dec; 104(12):5843-5852. PubMed ID: 31298706
[TBL] [Abstract][Full Text] [Related]
33. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
34. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
35. 68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia.
Parihar AS; Vadi SK; Kumar R; Mittal BR; Singh H; Bal A; Walia R; Shukla J; Sinha SK
Clin Nucl Med; 2018 Aug; 43(8):e285-e286. PubMed ID: 29877881
[TBL] [Abstract][Full Text] [Related]
36. Volume Replacement Fluid Demarks Benign Insulinoma With 68Ga-DOTA-Exendin-4 PET/CT.
Antwi K; Nicolas G; Fani M; Christ E; Wild D
Clin Nucl Med; 2019 May; 44(5):e347-e348. PubMed ID: 30889001
[TBL] [Abstract][Full Text] [Related]
37. Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.
Shah R; Garg R; Majmundar M; Purandare N; Malhotra G; Patil V; Ramteke-Jadhav S; Lila A; Shah N; Bandgar T
Clin Endocrinol (Oxf); 2021 Aug; 95(2):354-364. PubMed ID: 33386617
[TBL] [Abstract][Full Text] [Related]
38. Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.
Mi B; Xu Y; Pan D; Wang L; Yang R; Yu C; Wan W; Wu Y; Yang M
Biochem Biophys Res Commun; 2016 Feb; 471(1):47-51. PubMed ID: 26850848
[TBL] [Abstract][Full Text] [Related]
39. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
Chang L; Bi X; Li S; Tong Q; Gu Y; He Z; Li Y; Chen Q; Cui J; Yu H; He Q; Liu M
Front Endocrinol (Lausanne); 2023; 14():1163176. PubMed ID: 37455905
[TBL] [Abstract][Full Text] [Related]
40. Application of Ga(68) -DOTA-exendin-4 PET/CT to localize an occult insulinoma.
Cuthbertson DJ; Banks M; Khoo B; Antwi K; Christ E; Campbell F; Raraty M; Wild D
Clin Endocrinol (Oxf); 2016 May; 84(5):789-91. PubMed ID: 26562613
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
